While BTK inhibition typically involves time-unlimited therapy, combining it with BCL-2 inhibitors can offer ... patients with relapsed/refractory mantle cell lymphoma (MCL) who previously received at ...

Venetoclax is the first-in-class B-cell lymphoma 2 (BCL-2) inhibitor and triggers apoptosis selectively in cells reliant on the BCL-2 pathway for survival. Randomized clinical trials have established ...

Like a creature from a science fiction movie, chronic lymphocytic leukemia (CLL) can be a shape-shifter. In a small number of ...

Gilead Sciences’ Kite Pharma unit is closing on approval of its second European approval for a CAR-T for cancer, after the CHMP backed its KTE-X19 therapy for mantle cell lymphoma. The EMA’s ...

AMPLIFY is testing BTK inhibitor Calquence (acalabrutinib) in combination with AbbVie/Roche's BCL-2 inhibitor Venclexta ... as well as for mantle cell lymphoma. It has become AZ's third biggest ...

Primary large B-cell lymphomas of immune-privileged sites (IP-LBCLs) include primary central nervous system large B-cell lymphoma (PCNSL), primary vitreoretinal ... evidence for the clinical ...

John Seymour, MBBS, FRACP, PhD, explains why BCL-2 was considered an undruggable target for so long and what led to the development of effective BCL-2 inhibitors.

Discover the long-term results of CAR T-cell therapy, with and without stem cell transplantation, for relapsed lymphoma ...

This type affects 1 in 20 people with lymphoma and is more common in older adults and men. It forms in your spleen, lymph nodes, or bone marrow. Mantle cell lymphoma grows slowly but can be hard ...